Skip to main content
. 2017 Oct 4;8(56):95554–95567. doi: 10.18632/oncotarget.21481

Figure 3. qRT-PCR validation of the sequencing results.

Figure 3

qRT-PCR validation of 10 differentially expressed lncRNAs (A) and mRNAs (B). Control group represents PBS, experimental group represents HQ 20μmol/L. (A) Compared to control group, c11orf92, ENSG00000272259.1, LILRP2, LOC344887, LGALS9, HBBP1, ENSG00000270164.1 were significantly differentially expressed. Among them, LILRP2, LOC344887, LGALS9, HBBP1, ENSG00000270164.1 expression changes consistent with the sequencing results. (B) Compared to control group, FUT1, INHBE, SLC7A11, MROH5, METTL7B, MDM2 were significantly differentially expressed. Among them, FUT1, INHBE, SLC7A11, MROH5, MDM2 expression changes consistent with the sequencing results. The expressions of LOC344887 (C) and ENSG00000270164.1 (LINC01480) (D) were validated by qRT-PCR at different concentrations of HQ (24h and 48h). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.